Anaptysbio, INC Form 4 insider transactions

Paul F. Lizzul, Chief Medical Officer of Anaptysbio, Inc, received 16,667 shares of common stock on March 12, 2026.

Daniel Faga, President, CEO and a Director of Anaptysbio, Inc, received 53,334 shares of common stock on March 12, 2026.

AnaptysBio, Inc. Director John P. Schmid acquired 6,030 restricted stock units on June 15, 2026, with full vesting scheduled for June 15, 2026.

AnaptysBio Director John Orwin acquired 6,030 restricted stock units, vesting fully on June 15, 2026.

Director Owen Hughes was granted 11,250 restricted stock units in AnaptysBio, Inc. as part of standard equity compensation.

AnaptysBio CFO Christopher M. Murphy was granted 25,765 restricted stock units as part of an equity compensation plan.

CEO Daniel Faga filed an amendment to a Form 4 to correct the reported number of stock options held.

Director John A. Orwin reports adjustments to stock options following the spin-off of First Tracks.

Director John P. Schmid adjusted his stock option holdings following the spin-off of First Tracks.

Director Renton Hollings adjusted stock option holdings following the spin-off of First Tracks.

CEO Dan Faga adjusted his stock option holdings following the spin-off of First Tracks from AnaptysBio.

AnaptysBio, Inc. has completed the spin-off of its subsidiary, First Tracks Biotherapeutics, Inc., distributing all shares of First Tracks common stock to AnaptysBio shareholders.

ANAPTYSBIO Director John P. Schmid sold 20,645 shares of common stock in multiple transactions under a pre-arranged 10b5-1 plan.

ANAPTYSBIO's President and CEO, Daniel Faga, reported the vesting of performance-based restricted stock units and subsequent 'sell to cover' transactions to satisfy tax obligations.

AnaptysBio Director Magda Marquet exercised stock options and subsequently sold a portion of her common stock holdings.

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, reported the vesting of 8,525 restricted stock units and a subsequent sale of 3,650 shares to cover tax obligations.

AnaptysBio's Chief Financial Officer, Dennis Mulroy, reported the vesting of 6,700 restricted stock units and a subsequent sale of 2,515 shares to cover tax withholding obligations.

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, acquired shares through RSU settlement and subsequently sold a portion to cover tax withholding obligations.

ANAPTYSBIO CEO Daniel Faga reported the acquisition of 26,838 shares from RSU vesting and the sale of 14,281 shares to cover tax obligations.

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, reported the acquisition of new restricted stock units and stock options, alongside sales of common stock, some for tax obligations and others under a 10b5-1 plan.

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, reported the vesting and settlement of restricted stock units, a related tax-driven share sale, and new grants of restricted stock units and stock options.

AnaptysBio CEO Daniel Faga reported the vesting of restricted stock units, a subsequent 'sell to cover' transaction for tax obligations, and new grants of restricted stock units and stock options.

AnaptysBio's Chief Financial Officer, Dennis Mulroy, reported the acquisition of new equity awards and a 'sell to cover' transaction for tax obligations.

AnaptysBio, Inc. Director Dennis M. Fenton was granted 5,500 stock options and 4,000 restricted stock units on January 6, 2026.

ANAPTYSBIO, INC. Director Rita Jain acquired 5,500 stock options and 4,000 restricted stock units, signaling increased insider ownership.

AnaptysBio Director Magda Marquet received 5,500 stock options and 4,000 restricted stock units as part of her compensation.

AnaptysBio Director Hollings Renton was granted 5,500 stock options and 4,000 restricted stock units.

ANAPTYSBIO, INC. director John P. Schmid received grants of 5,500 stock options and 4,000 restricted stock units as part of his compensation.

AnaptysBio, Inc. Director J. Anthony Ware was granted 5,500 stock options and 4,000 restricted stock units on January 6, 2026.

ANAPTYSBIO, INC. Director John A. Orwin was granted 8,250 stock options and 6,000 restricted stock units on January 6, 2026.